This is a truly transformative time for Peregrine.
We are transitioning from an early-stage research organization to a late-stage drug development company, thanks
to an expanding product pipeline that now includes two Phase III-ready programs, exceptional proof-of-concept
clinical data for our lead product candidate bavituximab and a record-breaking revenue year for our contract
manufacturing business. Taken together, this has been an exciting year of growth that has set the stage for success
now and into the future.
By diligently executing our strategy, today we are positioned with two advanced programs from our oncologyfocused
pipeline ready for Phase III development. Over the last year, we made great strides in exploring the
potential of our proprietary phosphatidylserine (PS)-targeting platform including our lead PS-targeting antibody
bavituximab and in advancing our other business goals. Achievements over the past year included:...